Evidence map›Paper›PMID 38328603›Full record

ArticleCancer pathogenesis and therapy2023

Next-generation sequencing revealed factors associated with cumulative incidence of relapse and leukemia-free survival in patients with newly diagnosed acute myeloid leukemia.

Sai Huang, Peng Chen, Lu Wang, Lingmin Xu, Mingyu Jia, Jing Chen, Nan Wang, Fei Li, Lixia Liu, Jiayue Qin and 4 more

Expression of concernAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer pathogenesis and therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It carries an expression of concern. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors.

Sai HuangDepartment of Hematology, Senior Department of Hematology, The Fifth Medical Center of PLA General Hospital, Beijing 100039, China.
Peng ChenDepartment of Hematology, Senior Department of Hematology, The Fifth Medical Center of PLA General Hospital, Beijing 100039, China.
Lu WangDepartment of Hematology, The First Medical Center of PLA General Hospital, Beijing 100853, China.
Lingmin XuDepartment of Hematology, The First Medical Center of PLA General Hospital, Beijing 100853, China.
Mingyu JiaDepartment of Hematology, The First Medical Center of PLA General Hospital, Beijing 100853, China.
Jing ChenDepartment of Hematology, The First Medical Center of PLA General Hospital, Beijing 100853, China.
Nan WangChinese PLA Medical School, Beijing 100853, China.
Fei LiDepartment of Hematology, The First Medical Center of PLA General Hospital, Beijing 100853, China.
Lixia LiuAcornmed Biotechnology Co., Ltd., Tianjin 301700, China.
Jiayue QinAcornmed Biotechnology Co., Ltd., Tianjin 301700, China.
Chengcheng WangAcornmed Biotechnology Co., Ltd., Tianjin 301700, China.
Shanbo CaoAcornmed Biotechnology Co., Ltd., Tianjin 301700, China.
Liping DouDepartment of Hematology, Senior Department of Hematology, The Fifth Medical Center of PLA General Hospital, Beijing 100039, China.
Daihong LiuDepartment of Hematology, Senior Department of Hematology, The Fifth Medical Center of PLA General Hospital, Beijing 100039, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Several prognostic biomarkers have been validated for acute myeloid leukemia (AML), a heterogeneous hematopoietic malignancy. However, the factors associated with the cumulative incidence of relapse (CIR) and leukemia-free survival (LFS) in real-world patients with AML have not been well defined. Methods: This study examined clinical and mutational data of 246 patients with newly diagnosed AML who received the traditional "3 ​+ ​7" regimen in PLA General Hospital from January 2008 to August 2020. Factors associated with CIR and LFS in patients newly diagnosed with AML were analyzed using next-generation sequencing. Results: Additional sex combs-like 1 ( Conclusion: These findings indicate that patients with

Indexed as

Acute myeloid leukemiaInduction regimenNext-generation sequencingPrognostic impact

Identifiers

PMID38328603
PMCPMC10846322

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.